Showing results (111-120 of 196) with videos related to

Sort By:
Pageof 20
Therapeutic Advances in Chronic Disease|January 24, 2022
Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case reportMaria d'Apolito, Rocco Spagnuolo, Maria Anna Siciliano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2005
Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myelomaPierfrancesco Tassone, Paola Neri, Renate Burger, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 14, 2010
Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapyPierpaolo Correale, Maria Saveria Rotundo, Maria Teresa Del Vecchio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 2013
Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growthEmanuela Leone, Eugenio Morelli, Maria T Di Martino, et al.
Oncotarget|May 21, 2014
Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activityLavinia Raimondi, Nicola Amodio, Maria Teresa Di Martino, et al.
International Journal of Cancer|July 28, 2007
The farnesyltransferase inhibitor R115777 (ZARNESTRA) enhances the pro-apoptotic activity of interferon-alpha through the inhibition of multiple survival pathwaysMichele Caraglia, Monica Marra, Caterina Viscomi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2008
Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial)Pierpaolo Correale, Pierosandro Tagliaferri, Antonella Fioravanti, et al.
European Journal of Haematology|February 19, 2025
Relapsed/Refractory Follicular Lymphoma: Current Advances and Emerging PerspectivesGiulio Caridà, Enrica Antonia Martino, Antonella Bruzzese, et al.
Cancer Chemotherapy and Pharmacology|November 27, 2015
Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysisMariamena Arbitrio, Maria Teresa Di Martino, Vito Barbieri, et al.
British Journal of Haematology|July 1, 2026
Clinical outcomes of the chemo-free approach in relapsed/refractory follicular lymphoma: A network meta-analysisDaniele Caracciolo, Maria Rita Lombardo, Gianluca Reitano, et al.
Pageof 20